



## Novartis Community Update – Zolgensma® Health Canada approval

December 16, 2020

As requested, and as part of our ongoing commitment to keep you informed of important milestones regarding Zolgensma® (onasemnogene abeparvovec), we are so pleased to share that Health Canada has approved Zolgensma for babies and children with spinal muscular atrophy.

More specifically, the treatment is approved for pediatric patients with 5q spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 (*SMN1*) gene and 3 or fewer copies of *SMN2* gene; or infantile-onset SMA.

Today's announcement celebrates a milestone in our journey to tackle the unmet needs of those diagnosed with SMA. Novartis takes our obligation to the SMA community seriously and on behalf of our colleagues, we're honoured that we could make this moment happen.

Our work is not done. We believe that all children who could benefit from Zolgensma should be able to access it. This is why we continue to work collaboratively with the pan-Canadian Pharmaceutical Alliance, and provinces and territories to make this happen as quickly as possible.

Thank you for the continued interest in Zolgensma. We will publicly communicate updated information on our activities and key milestones wherever possible.

Sincerely,

Andrea Marazzi  
Country Head  
Novartis Pharmaceuticals Canada Inc.

Brent Warner  
Vice President, Gene Therapy and Rare Diseases  
Novartis Pharmaceuticals Canada Inc.